Growing Demand for Bioburden Testing With Growth in the Medical Devices, Pharmaceutical, and Biotechnology Industries
What This Report Will Provide? This study involved four major activities in estimating the current size of the bioburden testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
Expected Revenue Growth: [129 Pages Report] MarketsandMarkets forecasts the bioburden testing market to grow from USD 1.10 billion by 2023 from USD 0.61 billion in 2018, at a Compound Annual Growth Rate (CAGR) of 12.4%
Major Growth Boosters: The market is witnessing growth due to factors such as growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination are expected to drive the growth of this market during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17983056
Recent Developments: In 2018, Charles River acquired MPI Research, is a premier non-clinical contract research organization (CRO). This acquisition enhanced Charles River’s ability to partner with clients across the drug discovery and development continuum.
In 2016, Charles River acquired WIL Research, is a premier provider of safety assessment and contract development and manufacturing (CDMO) services. This acquisition strengthened the company’s position as a leading global early-stage CRO
In 2016, SGS acquired Quality Compliance Laboratories to provide microbiological and analytical testing to the pharmaceutical, nutraceutical, and cosmeceutical industries
In 2015, Merck KGaA acquired Sigma-Aldrich Corporation (US) to expand its life science research product portfolio
Regional Growth Analysis: The market is dominated by North America, followed by Europe, Asia, and RoW. North America is expected to continue to dominate this market in the forecast period. The large size of the North American biotechnology industry will aid in the growth of the bioburden testing market in this region.
Key Questions Addressed in The Report: 1. Who are the top 10 players operating in the global bioburden testing market?
2. What are the drivers, restraints, opportunities, and challenges in the bioburden testing Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of bioburden testing in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=17983056 Key Players:
The bioburden testing market is competitive in nature, with several big as well as emerging players. Prominent players in this market include Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson, and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific, Inc. (US), Biomérieux SA (France), and Pacific BioLlabs (US).